两种抗血栓机制不同的中线导管装置与导管相关血栓比较:一项随机临床试验
该平行双组随机临床试验在郊区学术医学中心纳入212例接受中线导管的成人住院患者,最终分析191例(MC-AT组94例,MC-AT-AM组97例)。主要终点为置管后30天内症状性中线导管相关血栓(含深静脉血栓或浅表血栓性静脉炎)。MC-AT组7例(7.5%) vs MC-AT-AM组11例(11.3%)发生症状性导管相关血栓(P=.46),深静脉血栓各5例(5.3% vs 5.2%,P>.99),MC-AT组1例发生肺栓塞。两组均无导管相关血流感染,导管提前失效MC-AT组22例(23.4%) vs MC-AT-AM组20例(20.6%)(P=.64),Cox回归风险比1.27(95%CI 0.67-2.43;P=.46)。作者认为两种抗血栓机制不同的中线导管血栓发生率无差异,但两组导管相关血栓风险均高,选择血管通路装置时应强烈考虑中线导管的安全风险。
要点
- 最终分析191例成人住院患者:MC-AT组94例、MC-AT-AM组97例,置管后30天内症状性中线导管相关血栓发生率7.5% vs 11.3%(P=.46),无显著差异。
- 深静脉血栓发生率MC-AT组5.3% vs MC-AT-AM组5.2%(P>.99),MC-AT组1例发生肺栓塞。
- 两组均无导管相关血流感染;导管提前失效MC-AT组23.4% vs MC-AT-AM组20.6%(P=.64),Cox回归HR 1.27(95%CI 0.67-2.43;P=.46)。
- 作者认为两种抗血栓机制不同的中线导管血栓发生率无差异,但两组导管相关血栓风险均高,选择血管通路装置时应强烈考虑中线导管的安全风险。
适用人群与场景
- 2019年1月1日至2020年10月31日在郊区学术医学中心住院并接受中线导管的成人患者。
- 最终分析191例:MC-AT组94例、MC-AT-AM组97例;平均(SD)年龄60.2(16.7)岁,女性114例(59.7%)。
处置流程与药物剂量
- 随机分配至4F抗血栓中线导管(MC-AT)组或4.5F抗血栓及抗菌中线导管(MC-AT-AM)组。
- 主要终点为置管后30天内症状性中线导管相关血栓,包括深静脉血栓或浅表血栓性静脉炎。
研究设计与关键结果
- 平行双组随机临床试验,2019年1月1日至2020年10月31日评估496例成人住院患者资格,212例随机化,最终分析191例(MC-AT组94例、MC-AT-AM组97例)。
- 症状性中线导管相关血栓:MC-AT组7例(7.5%) vs MC-AT-AM组11例(11.3%)(P=.46)。
- 深静脉血栓:MC-AT组5例(5.3%) vs MC-AT-AM组5例(5.2%)(P>.99)。
- 肺栓塞:MC-AT组1例;导管相关血流感染:两组均无发生。
- 导管提前失效:MC-AT组22例(23.4%) vs MC-AT-AM组20例(20.6%)(P=.64);Cox比例风险回归分析导管失效风险HR 1.27(95%CI 0.67-2.43;P=.46)。
证据类型、等级与局限
- 证据类型:平行双组随机临床试验(ClinicalTrials.gov标识NCT03725293)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,两种抗血栓机制不同的中线导管在血栓形成方面无差异,但两组导管相关血栓风险均高;在决定合适的血管通路装置时,应强烈考虑中线导管的安全风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Data regarding upper extremity midline catheter (MC)-related thrombosis (CRT) are sparse, with some evidence indicating that MCs have a high rate of CRT.
OBJECTIVE: To compare 2 MCs with differing antithrombogenic mechanisms for this outcome.
DESIGN, SETTING, AND PARTICIPANTS: In this parallel, 2-arm randomized clinical trial, 496 adult patients hospitalized at a tertiary care suburban academic medical center who received an MC were assessed for eligibility between January 1, 2019, and October 31, 2020, and 212 were randomized.
INTERVENTIONS: Inpatients were randomized to receive a 4F antithrombotic MC (MC-AT) or a 4.5F antithrombotic and antimicrobial MC (MC-AT-AM).
MAIN OUTCOMES AND MEASURES: The primary outcome was symptomatic midline CRT inclusive of deep vein thrombosis or superficial venous thrombophlebitis within 30 days after insertion. Secondary outcomes included catheter-associated bloodstream infection and catheter failure.
RESULTS: A total of 191 patients (mean [SD] age, 60.2 [16.7] years; 114 [59.7%] female) were included in the final analysis: 94 patients in the MC-AT group and 97 in the MC-AT-AM group. Symptomatic midline CRT occurred in 7 patients (7.5%) in the MC-AT group and 11 (11.3%) in the MC-AT-AM group (P = .46). Deep vein thrombosis occurred in 5 patients (5.3%) in the MC-AT group and 5 patients (5.2%) in the MC-AT-AM group (P > .99). Pulmonary embolism occurred in 1 patient in the MC-AT group. No catheter-associated bloodstream infection occurred in either group. Premature catheter failure occurred in 22 patients (23.4%) in the MC-AT group and 20 (20.6%) in the MC-AT-AM group (P = .64). In Cox proportional hazards regression analysis, no statistically significant difference was found between groups for the risk of catheter failure (hazard ratio, 1.27; 95% CI, 0.67-2.43; P = .46).
CONCLUSIONS AND RELEVANCE: No difference was found in thrombosis in MCs with 2 distinct antithrombogenic mechanisms; however, the risk of CRT in both groups was high. Practitioners should strongly consider the safety risks associated with MCs when determining the appropriate vascular access device.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03725293.
参考来源
- Bahl A, Diloreto E, Jankowski D, et al. Comparison of 2 Midline Catheter Devices With Differing Antithrombogenic Mechanisms for Catheter-Related Thrombosis: A Randomized Clinical Trial. JAMA Netw Open. 2021. PMID: 34613402. doi:10.1001/jamanetworkopen.2021.27836
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。